“Noids” in a nutshell: everything you (don’t) want to know about synthetic cannabimimetics

作者: Duccio Papanti , Laura Orsolini , Giulia Francesconi , Fabrizio Schifano

DOI: 10.1108/ADD-02-2014-0006

关键词:

摘要: Purpose – “Spice” products are synthetic cannabimimetics (SC; also called “synthetic cannabinoids”)-based designer drugs used as a legal alternative to cannabis for their very strong tetrahydrocannabinol (THC)-like effects. The purpose of this paper is to provide an analysis of more recent clinical and pharmacology/toxicology findings relating to SC and describe how they could impact on health, with a particular focus on mental health. Design/methodology/approach – A systematic search and descriptive analysis of the available evidence on psychopathological issues related to misuse was performed here, whilst taking into account the Pubmed/Medline databases, a range of conference proceedings and national/international agencies’ reports. Findings – While THC is a partial agonist, SC are full agonists on the cannabinoid receptors (CB-rs) and the administration of multiple SC can produce additive and/or synergistic agonistic interaction effects on the endocannabinoid system. These levels of strong CB-rs’ activation may be high enough to produce severe physiological and psychological disturbances. The available evidence suggests an existing relationship between SC use and psychosis (“Spiceophrenia”). The acute SC intoxication is usually characterized by tachycardia/hypertension; visual/auditory hallucinations; mydriasis; agitation/anxiety; tachypnoea; nausea/vomiting; and seizures. Research limitations/implications – The absence of clinical trials and longitudinal studies, together with the heterogeneity of SC compounds does not facilitate a precise assessment of the health risks related to their use, with long-term effects being of particular concern. Originality/value – Appropriate, non-judgemental, prevention campaigns with a special focus on the differences between SC and cannabis may need to be organized on a large scale. At the same time, clinicians need to be regularly updated about novel psychoactive substances, including SC, to promptly recognize signs/symptoms of intoxication.

参考文章(99)
Philip Seeman, Atypical Antipsychotics: Mechanism of Action: The Canadian Journal of Psychiatry. ,vol. 47, pp. 27- 38 ,(2002) , 10.1177/070674370204700106
Ornella Corazza, Fabrizio Schifano, Suzanne Fergus, Sulaf Assi, Jacqueline Stair, Emergence and identification of new products of designer drug products from the internet ,(2011)
Volker Auwärter, Paul I. Dargan, David M. Wood, Synthetic Cannabinoid Receptor Agonists Novel Psychoactive Substances#R##N#Classification, Pharmacology and Toxicology. pp. 317- 343 ,(2013) , 10.1016/B978-0-12-415816-0.00013-4
Leo Schep, Sultan Al-Shaqsi, Brad Strong, Paul Glue, Chris Gale, Douglas Hancock, Hospitalisation associated with use of the synthetic cannabinoid K2 The New Zealand Medical Journal. ,vol. 126, pp. 18- 23 ,(2013)
Paul I. Dargan, David M. Wood, Novel psychoactive substances: classification, pharmacology and toxicology. Academic Publishing. ,(2013)
Duccio Papanti, Fabrizio Schifano, Giulia Botteon, Francesca Bertossi, Jason Mannix, Daniela Vidoni, Matteo Impagnatiello, Elisabetta Pascolo-Fabrici, Tommaso Bonavigo, “Spiceophrenia”: a systematic overview of “Spice”‐related psychopathological issues and a case report Human Psychopharmacology-clinical and Experimental. ,vol. 28, pp. 379- 389 ,(2013) , 10.1002/HUP.2312
Stephanie Peglow, Jessica Buchner, Gregory Briscoe, Synthetic cannabinoid induced psychosis in a previously nonpsychotic patient. American Journal on Addictions. ,vol. 21, pp. 287- 288 ,(2012) , 10.1111/J.1521-0391.2012.00222.X
Daniel T Malone, Matthew N Hill, Tiziana Rubino, Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental models British Journal of Pharmacology. ,vol. 160, pp. 511- 522 ,(2010) , 10.1111/J.1476-5381.2010.00721.X
Maren Hermanns-Clausen, Stefan Kneisel, Bela Szabo, Volker Auwärter, Acute toxicity due to the confirmed consumption of synthetic cannabinoids: clinical and laboratory findings Addiction. ,vol. 108, pp. 534- 544 ,(2013) , 10.1111/J.1360-0443.2012.04078.X
Pierluigi Simonato, Ornella Corazza, Paolo Santonastaso, John Corkery, Paolo Deluca, Zoe Davey, Ursula Blaszko, Fabrizio Schifano, Novel psychoactive substances as a novel challenge for health professionals: results from an Italian survey Human Psychopharmacology-clinical and Experimental. ,vol. 28, pp. 324- 331 ,(2013) , 10.1002/HUP.2300